TY - JOUR
T1 - Emerging treatment strategies for glioblastoma multiforme
AU - Carlsson, Steven K.
AU - Brothers, Shaun P.
AU - Wahlestedt, Claes
N1 - Publisher Copyright:
© 2014 The Authors. Published under the terms of the CC BY 4.0 license.
Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Glioblastoma multiforme (GBM) is the deadliest form of brain tumor with a more than 90% 5-year mortality. GBM has a paltry median survival of 12.6 months attributed to the unique treatment limitations such as the high average age of onset, tumor location, and poor current understandings of the tumor pathophysiology. The resection techniques, chemotherapic strategies, and radiation therapy currently used to treat GBM have slowly evolved, but the improvements have not translated to marked increases in patient survival. Here, we will discuss the recent progress in our understanding of GBM pathophysiology, and the diagnostic techniques and treatment options. The discussion will include biomarkers, tumor imaging, novel therapies such as monoclonal antibodies and small-molecule inhibitors, and the heterogeneity resulting from the GBM cancer stem cell population. A comprehensive overview and discussion of our current understanding of glioblastoma multiforme (GBM) pathophysiology and heterogeneity, diagnostic techniques and treatment options, including novel therapies such as monoclonal antibodies and small-molecule inhibitors.
AB - Glioblastoma multiforme (GBM) is the deadliest form of brain tumor with a more than 90% 5-year mortality. GBM has a paltry median survival of 12.6 months attributed to the unique treatment limitations such as the high average age of onset, tumor location, and poor current understandings of the tumor pathophysiology. The resection techniques, chemotherapic strategies, and radiation therapy currently used to treat GBM have slowly evolved, but the improvements have not translated to marked increases in patient survival. Here, we will discuss the recent progress in our understanding of GBM pathophysiology, and the diagnostic techniques and treatment options. The discussion will include biomarkers, tumor imaging, novel therapies such as monoclonal antibodies and small-molecule inhibitors, and the heterogeneity resulting from the GBM cancer stem cell population. A comprehensive overview and discussion of our current understanding of glioblastoma multiforme (GBM) pathophysiology and heterogeneity, diagnostic techniques and treatment options, including novel therapies such as monoclonal antibodies and small-molecule inhibitors.
KW - Biomarkers
KW - Brain imaging
KW - Cancer stem cells
KW - Epigenetics
KW - Glioblastoma multiforme (GBM)
UR - http://www.scopus.com/inward/record.url?scp=84910597102&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84910597102&partnerID=8YFLogxK
U2 - 10.15252/emmm.201302627
DO - 10.15252/emmm.201302627
M3 - Review article
C2 - 25312641
AN - SCOPUS:84910597102
VL - 6
SP - 1359
EP - 1370
JO - EMBO Molecular Medicine
JF - EMBO Molecular Medicine
SN - 1757-4676
IS - 11
ER -